Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Epratuzumab: targeting B-cell malignancies through CD22.

Morton Coleman1, David M Goldenberg, Abby B Siegel

  • 1Center for Lymphoma and Myeloma, Division of Hematology/Oncology, Weill Medical College of Cornell University, New York, New York 10021, USA. mortoncolemanmd@aol.com

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|September 25, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naïve Advanced Hepatocellular Carcinoma: Long-Term Follow-up of the Open-Label, Phase II KEYNOTE-224 Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study.

Cancer research communications·2026
Same author

Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinoma.

Annals of hepatology·2025
Same author

Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies.

JHEP reports : innovation in hepatology·2025
Same author

Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.

Lancet (London, England)·2025
Same author

Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.

NPJ breast cancer·2024

New monoclonal antibody therapies targeting CD22, like epratuzumab, show promise for treating B-cell non-Hodgkin

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • B cell-directed monoclonal antibody therapies have transformed B-cell non-Hodgkin's lymphoma (NHL) treatment.
  • Anti-CD20 antibodies offer manageable toxicity and complementary mechanisms to chemotherapy.
  • Targeting other B-cell antigens, such as CD22, presents a rationale for novel therapeutic strategies.

Purpose of the Study:

  • To explore the potential of targeting the CD22 antigen in B-cell malignancies.
  • To evaluate the antilymphoma activity of epratuzumab, a humanized anti-CD22 monoclonal antibody.

Main Methods:

  • Review of laboratory and initial clinical studies involving epratuzumab.
  • Assessment of epratuzumab's efficacy in both unlabeled and radiolabeled forms.
  • Exploration of single-agent and combination treatment regimens.

Related Experiment Videos

Main Results:

  • Epratuzumab demonstrates potential antilymphoma activity.
  • The antibody shows promise in both unlabeled and radiolabeled applications.
  • Ongoing efforts aim to define optimal clinical settings for epratuzumab use.

Conclusions:

  • Epratuzumab represents a promising therapeutic candidate for B-cell malignancies.
  • Further research is necessary to establish its utility in clinical practice.
  • Combination strategies and optimal application settings are under investigation.